Mobic Adds Juvenile RA Indication, Cardiovascular “Black Box” Warnings
Executive Summary
Addition of a juvenile rheumatoid arthritis indication to Boehringer Ingelheim's Mobic provided an opportunity to add class cardiovascular and gastrointestinal risk language to labeling for the nonsteroidal anti-inflammatory drug